Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2025-01-21 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about receiving an order from the Transfer Pricing Officer under the Income Tax Act for the Assessment Year 2022-23. The content is a regulatory announcement about a legal/tax dispute and does not contain financial statements or detailed financial data. It is not a full report but a regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-21 English
Press Release
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for a new pharmaceutical product. It is dated January 20, 2025, and is addressed to stock exchanges. The content focuses on the product approval and company information, with no financial data, regulatory certifications, or detailed financial reports. The document is relatively short (4095 characters) and serves as a public announcement rather than a detailed report or filing. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's product portfolio and market position, but it is not a financial report or earnings release. However, since it is a press release about product approval and not directly about financing or capital structure, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-01-20 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance under SEBI regulations about the issuance of a duplicate share certificate to a shareholder. It includes details of the shareholder, old and new certificate numbers, and proof of dispatch. There is no financial data, no report attached or referenced, and no mention of financial results or management discussion. The document is a regulatory compliance communication related to share certificates, which does not fit into financial reports, earnings, or management information categories. It is a regulatory announcement about share certificate issuance and procedural compliance under SEBI rules. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories. The document length is short and it is not an announcement of a report publication, so RPA is not suitable.
2024-12-27 English
Demerger
Regulatory Filings Classification · 95% confidence The document is a communication from Strides Pharma Science Limited to shareholders and stock exchanges regarding the Scheme of Arrangement (demerger) approved by the National Company Law Tribunal. It provides guidance on the apportionment of the Cost of Acquisition (COA) of equity shares post-demerger for tax purposes. The document references the Companies Act, 2013, and Income Tax Act, 1961, and explains how shareholders should split their COA between the original company and the resulting company shares. It is a detailed shareholder guidance letter related to a corporate restructuring event, not a financial report, earnings release, or regulatory certification. It is not a proxy solicitation, voting result, or management change announcement. It is also not a report publication announcement since it contains substantive guidance content. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory communication providing statutory guidance and information to shareholders about the scheme and tax implications, without being a formal financial report or announcement of voting results.
2024-12-11 English
Demerger
Capital/Financing Update Classification · 95% confidence The document is a formal communication from Strides Pharma Science Limited to stock exchanges regarding the allotment of equity shares by OneSource pursuant to a Scheme of Arrangement under the Companies Act. It details the share allotment ratio, next steps for share crediting, handling of fractional entitlements, and the expected timeline for listing approval. There are no financial statements, earnings data, or detailed financial analysis present. The document is an announcement about a corporate action related to share allotment and listing process following a scheme of arrangement, which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and it is not merely announcing the publication of a report but providing substantive information about the share allotment and next steps. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-12-11 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance under SEBI regulations about the issuance of duplicate share certificates to a shareholder. It includes details of old and new folio numbers, certificate numbers, and shares involved. There is no financial data, earnings information, or report content. The document is a regulatory compliance announcement related to share certificates, not a financial report or management information. It fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2024-12-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.